Curis, Inc. (NASDAQ:CRIS) Short Interest Down 54.4% in November

Curis, Inc. (NASDAQ:CRIS) was the recipient of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 74,100 shares, a drop of 54.4% from the November 15th total of 162,500 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average trading volume of 53,500 shares, the short-interest ratio is presently 1.4 days.

Curis Stock Performance

CRIS traded down $0.15 during midday trading on Friday, reaching $3.57. 47,426 shares of the company were exchanged, compared to its average volume of 42,347. The company has a market cap of $30.24 million, a price-to-earnings ratio of -0.46 and a beta of 3.34. Curis has a one year low of $3.50 and a one year high of $17.49. The company’s fifty day moving average price is $4.50 and its 200 day moving average price is $5.79.

Institutional Investors Weigh In On Curis

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Curis by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after acquiring an additional 10,097 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after purchasing an additional 96,256 shares in the last quarter. Finally, Focused Wealth Management Inc boosted its holdings in Curis by 63.1% during the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 20,908 shares during the last quarter. Institutional investors own 29.97% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Curis in a research note on Tuesday.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.